Bifogade filer
Q3 Rapport ENG (131120)
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Despite the impact from Covid-19, the last patient was recruited in November to the ongoing registration based phase III study, Xplore.
Xbrane Biopharma AB’s (publ.) (”Xbrane”) interim report for January - September 2020 is now available on the Company’s website, www.xbrane.com.
Financial summary third quarter 2020
- Revenue amounted to SEK 0.0 M (0.0).
- Other operating income amounted to SEK 5.2 M (1.4).
- EBITDA was SEK -55.8 M (-35.6*).
- R&D expenses amounted to SEK 52.0 M (31.4*). representing 83% (80*) of total operating expenses.
- The loss for the period was SEK -57.7 M (-38.0*).
- Earnings per share was SEK -2.99 (-2.63*).
- Cash and cash equivalents at the end of the period amounted to SEK 123.8 M (162.2).
Financial summary of first nine months 2020
- Revenue amounted to SEK 0.0 M (0.0).
- Other operating income amounted to SEK 15.4 M (4.4).
- EBITDA was SEK -157.4 M (-114.6*).
- R&D expenses amounted to SEK 144.7 M (101.3*) representing 81% (81) of total operating expenses.
- The loss for the period was SEK -163.0 M (-121,3*).
- Earnings per share was SEK -9.49 (-12.42*).
Significant events during the third quarter 2020
- An Extraordinary General Meeting on September 22 authorized the Board to decide on an issue corresponding to 20% dilution.
- Margareta Hagman entered the position as CFO from 30 September.
Significant events after the period
- As of the 11th of November, the last patient in the ongoing pivotal phase III trial XPLORE was recruited.
- Xbrane completed a directed share issue of approximately SEK 200 M. A number of Swedish and international institutional investors, including Swedbank Robur Fonder, TIN Fonder, Andra AP-fonden and Lancelot Asset Management have subscribed for shares in the directed share Issue.
*This period has been recalculated due to restatement, see Appendix 1 in the interim report for the effects.
Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on November 13, 2020, at 10.00 a.m. CET. See below link and call in details to the presentation below:
https://edge.media-server.com/mmc/p/jcuq48x6
Standard international: +44 (0) 2071 928338
UK (Local): +44 (0) 8444819752
UK (Tollfree): 08002796619
Sweden (Local): +46 (0) 856618467
Sweden (TollFree): 0200125160
US (LocaL): +1 6467413167
US (TollFreee): +1 8778709135
Confirmation Code: 1225339